[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 918,159,872
  • Shares Outstanding, K 941,741
  • Annual Sales, $ 65,179 M
  • Annual Income, $ 20,640 M
  • EBIT $ 31,522 M
  • EBITDA $ 33,519 M
  • 60-Month Beta 0.48
  • Price/Sales 14.26
  • Price/Cash Flow 39.26
  • Price/Book 29.80

Options Overview Details

View History
  • Implied Volatility 32.96% (+0.88%)
  • Historical Volatility 40.98%
  • IV Percentile 25%
  • IV Rank 29.26%
  • IV High 47.67% on 07/30/25
  • IV Low 26.88% on 09/04/25
  • Expected Move (DTE 7) 24.89 (2.62%)
  • Put/Call Vol Ratio 0.71
  • Today's Volume 38,844
  • Volume Avg (30-Day) 40,912
  • Put/Call OI Ratio 1.01
  • Today's Open Interest 356,491
  • Open Int (30-Day) 326,023
  • Expected Range 923.56 to 973.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $8.64
  • Number of Estimates 6
  • High Estimate $9.26
  • Low Estimate $7.83
  • Prior Year $6.31
  • Growth Rate Est. (year over year) +36.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
850.51 +11.52%
on 04/29/26
996.48 -4.82%
on 05/06/26
-4.85 (-0.51%)
since 04/08/26
3-Month
850.51 +11.52%
on 04/29/26
1,106.94 -14.32%
on 02/09/26
-109.73 (-10.37%)
since 02/06/26
52-Week
623.78 +52.05%
on 08/08/25
1,133.95 -16.36%
on 01/08/26
+197.00 (+26.22%)
since 05/08/25

Most Recent Stories

More News
HHS Explored Potential SSRI Restrictions Ahead of RFK Jr. Push to Reduce Antidepressant Use

U.S. health officials recently explored whether certain selective serotonin reuptake inhibitors, or SSRIs, could face restrictions as Health Secretary Robert F. Kennedy Jr. prepared a broader initiative...

LLY : 948.45 (-2.72%)
PFE : 25.68 (-1.42%)
ELV : 378.07 (+1.38%)
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims

The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.

NVO : 46.07 (+0.59%)
LLY : 948.45 (-2.72%)
Biotech’s Next Wave May Already be in Motion

DENVER, May 07, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com and NeOnc Technology) - The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction,...

NTHI : 5.45 (-16.02%)
NVO : 46.07 (+0.59%)
LLY : 948.45 (-2.72%)
REGN : 714.89 (+0.82%)
Do Wall Street Analysts Like Eli Lilly Stock?

While Eli Lilly has slightly lagged behind the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

XLV : 143.49 (-0.85%)
$SPX : 7,398.93 (+0.84%)
LLY : 948.45 (-2.72%)
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility

Lilly's capital commitments to expand manufacturing in its home state now total $21 billion since 2020

LLY : 948.45 (-2.72%)
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years

In LUCENT-3, more than 60% of patients who achieved disease clearance at one year maintained it after four years of continuous Omvoh treatment

LLY : 948.45 (-2.72%)
3 Quality Compounders to Own for Decades

3 Quality Compounders to Own for Decades

RDDT : 155.80 (-4.97%)
LLY : 948.45 (-2.72%)
HOOD : 77.03 (+0.98%)
Lilly declares second-quarter 2026 dividend

INDIANAPOLIS , May 4, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2026 of $1.73 per share on outstanding common...

LLY : 948.45 (-2.72%)
Dear Veeva Systems Stock Fans, Mark Your Calendar for May 7

Veeva Systems stock pops following S&P 500 inclusion announcement.

$SPX : 7,398.93 (+0.84%)
MRK : 111.38 (-0.82%)
VEEV : 166.34 (-1.14%)
LLY : 948.45 (-2.72%)
DVN : 45.61 (+0.66%)
CTRA : 32.56 (-8.62%)
Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent

Eli Lilly's 2026 is off to a great start, with massive earnings and revenue beats and exciting updates about its latest GLP-1, Foundayo.

NVO : 46.07 (+0.59%)
LLY : 948.45 (-2.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 1,002.29
2nd Resistance Point 991.14
1st Resistance Point 969.80
Last Price 948.45
1st Support Level 937.31
2nd Support Level 926.16
3rd Support Level 904.82

See More

52-Week High 1,133.95
Last Price 948.45
Fibonacci 61.8% 939.07
Fibonacci 50% 878.86
Fibonacci 38.2% 818.66
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.